Home/Filings/3/0000899243-22-016348
3//SEC Filing

Versant Vantage II, L.P. 3

Accession 0000899243-22-016348

CIK 0001544227other

Filed

May 2, 8:00 PM ET

Accepted

May 3, 5:07 PM ET

Size

9.1 KB

Accession

0000899243-22-016348

Insider Transaction Report

Form 3
Period: 2022-04-29
Holdings
  • Common Stock

    2,118,644
Holdings
  • Common Stock

    2,118,644
Holdings
  • Common Stock

    2,118,644
Footnotes (2)
  • [F1]Represents shares acquired pursuant to a Securities Purchase Agreement dated April 26, 2022 between the Issuer, Versant Vantage II, L.P. ("Vantage II") and certain other investors. Not included on this Form 3 are an additional 997,940 shares of Common Stock held by Versant Venture Capital VI, L.P. ("VVC VI"), 1,171,094 shares of Common Stock held by Versant Venture Capital IV, L.P. ("VVC IV") and 7,377 shares of Common Stock held by Versant Side Fund IV, L.P. ("VSF IV"). Vantage II, VVC VI, VVC IV and VSF IV, along with their respective general partner entities, have filed a Form 4 on the date hereof reporting their respective holdings in a consolidated filing.
  • [F2]These shares are held of record by Vantage II. Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP, Vantage II GP and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.

Issuer

Tempest Therapeutics, Inc.

CIK 0001544227

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001832235

Filing Metadata

Form type
3
Filed
May 2, 8:00 PM ET
Accepted
May 3, 5:07 PM ET
Size
9.1 KB